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Abstract
This work aims to synthesize chitosan from locally available cowry and crab shells for Pharmaceutical application 
in drug delivery. Chitosan was synthesized from both shells using standard deacetylation technique. The synthesized 
chitosan, piroxicam and lactose were employed in preparing the drug loaded tablets by direct compression technique 
and subjected to characterization with the aid of Fourier Transform Infrared Spectroscopy (FTIR), Scanning Electron 
Spectroscopy (SEM) and optical microscopy. Finally, the drug release rate was investigated with in vitro drug 
dissolution test. The results of FTIR spectra confirmed that the biopolymer extract was chitosan and it also shows 
that there was no interaction between chitosan and the piroxicam. The morphological properties of the samples were 
found to be suitable for drug delivery. The applied load and composition of tablets influenced the drug release rates. 
Keywords: Piroxicam; Cowry shell; Drug delivery; Crab shell; Chi-
tosan
Introduction
The National Institutes of Health Consensus Development 
Conference defined a biomaterial as ‘‘any substance (other than a drug) 
or combination of substances, synthetic or natural in origin, which can 
be used for any period of time, as a whole or as a part of a system which 
treats, augments, or replaces any tissue, organ, or function of the body’’ 
(10) while Williams defined a biomaterial as a nonviable material used 
in a medical device, intended to interact with biological systems (36). 
Some of the main areas of applications of biomaterials are classified into:
• Cardiovascular medical devices (stents, grafts and etc.)
• Orthopedic and dental applications (implants, tissue engineered 
scaffolds and etc.)
• Ophthalmologic applications (contact lenses, retinal prostheses 
and etc.)
• Bio-electrodes and biosensors.
• Burn dressings and skin substitutes.
• Sutures.
• Drug delivery systems.
However, this work focuses on the application of biomaterial in drug 
delivery systems (DDS). Drug delivery systems introduced as formulations 
or instruments which enable to control the release rate of a biological 
agent (most especially a drug) in the target site. Drug delivery systems 
are an interface between patient and drug. Drugs can be introduced to 
the organ by various anatomical routes due to disease and drug type: 
Digestive system (oral, anal), oral, rectal, parenteral (subcutaneous, 
intramuscular, intravenous, arterial), mucous membranes, respiratory 
tract by inhalation, subcutaneous or intraosseous are man anatomical 
routes [1-12]. The various classifications of controlled released systems 
are indicated in Table 1 [13-24].
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) 
used in treatment of different types of arthritis such as osteoarthritis, 
rheumatoid arthritis, ankylosing spondylitis and acute gout disease 
[14]. It has a plasma half-life of approximately 50 hrs [25-30]. The 
chemical name for piroxicam is 4-hydroxy-2-methyl-N-2-pyridinyl-
2H-1,2 benzothiazine-3-carboxamide 1,1-dioxide. It is a member of the 
oxicam family, which though not carboxylic acids, are acidic by virtue 
of the enolic 4-hydroxy substituent (Figure 1). Piroxicam has poor 
solubility in water and when administered orally remains un-dissolve 
in the acidic environment such as obtained in the stomach causing 
bioavailability problems which may consequently lead to delay in the 
Type of system Rate-control mechanism
Diffusion control  reservoir 
devices Diffusion through membrane
Monolithic devices Diffusion through bulk polymer
Water penetration 
controlled osmotic systems
Osmotic transport of water through semi permeable 
membrane
Swelling systems Water penetration into glassy polymer
Chemically controlled 
monolithic systems
Either pure polymer erosion (surface erosion) or 
combination of erosion and diffusion (bulk erosion
Pendant chain systems Combination of hydrolysis of pendant group and diffusion from bulk polymer
Regulated systems 
magnetic or ultrasound
External application of magnetic field or ultrasound 
to device.
Chemical Use of competitive desorption or enzyme-substrate reactions. Rate control is built into device.
Table 1: Classifications of controlled released systems.
Citation: Akinwole IE, Oyatogun GM, Adenigba AE, Ayodele TJ, Oluwasegun KM, et al. (2018) Synthesis and Characterization of Cowry and Crab 
Shells Based Chitosan for Drug Delivery. Bioceram Dev Appl 8: 107. doi: 10.4172/2090-5025.1000107
Page 2 of 6
Volume 8 • Issue 1 • 1000107Bioceram Dev Appl, an open access journalISSN: 2090-5025
onset of drug effect [31-34]. In order to overcome these problems, it 
becomes necessary to develop a drug delivery system that will improve 
the solubility of piroxicam in the stomach. 
Polymers are extensively used for the drug delivery. It has been 
established that they have the ability to form a matrix, or a membrane, 
that can control the release of drugs over a prolonged period, thus 
avoiding repetitive dosing. They have also been used to form (nano) 
carriers to deliver drugs with low solubility or biotechnology-based 
drugs [23,25]. Biodegradable polymers have found wide applications in 
drug delivery due to the ease of removal of the carrier after the release of 
the active pharmaceutical ingredients. To avoid side effects, especially 
when the carrier is injected, the polymer must be biocompatible. On 
this basis, natural polymers such as polysaccharides, polypeptides, 
or phospholipids are generally used as building blocks for drug 
formulations [8,20,31,35-38]. 
Chitosan is a nontoxic, biodegradable and biocompatible linear 
polysaccharide composed of randomly distributed β-(1→4)-linked 
D-glucosamine (Figure 2) that has found diverse applications in drug 
delivery [23,27,28,32,33]. Over the last few decades, investigations had 
been focused on applications of chitosan and its fabricated products in 
drug delivery [2,13,35]. 
This study is therefore aimed at utilization of chitosan that will 
be synthesized from locally sourced crab and cowry shells, as a drug 
delivery vehicle that will enhance the bioavailability of piroxicam while 
simultaneously facilitating the controlled release of the drug [11,29].  
Materials and Methods
Materials
The materials used were cowry shells and crab shells (sourced from 
Bode market, Challenge, Ibadan, South Western Nigeria), hydrochloric 
acid, sodium hydroxide, (BDH Chemicals Ltd Poole, England), 
acetone (Sigma-Aldrich Laborchemickalien GMBH, Seelze, Germany), 
piroxicam (Bond Chemicals, Awe, Nigeria), lactose, magnesium 
stearate, talc (Merck KGaA, Darmstadt, Germany) and di-potassium 
hydrogen orthophosphate (BDH Chemicals Ltd Poole, England).
Methods 
The work entails the extraction of chitosan from cowry and crab 
shells, formulation of drug, and characterization of the synthesized 
chitosan and formulated tablet. This was with a view to ascertaining 
the suitability of the chitosan obtained from both shells for controlled 
drug delivery.  
Chitosan synthesis: The cowry and crab shells were thoroughly 
washed to remove impurities such as sand, dirt and insect larva and 
subsequently oven-dried at 60°C. The washed and dried shells were 
then pulverized using a Rocklabs mill to pass through a 250 μm sieve. 
Deproteinization of the shell was carried out by weighing eighty grams 
of the pulverized shells into a conical flask and adding 0.1 M sodium 
hydroxide to it. The mixture was boiled and stirred at 100ºC for 2 h 
in a water bath to remove the protein. The product was decolorized 
by soaking in pure acetone for 24 h. It was then sieved with 300 µm 
sieve, washed to neutrality and dried in the oven at 100ºC for 2 h. This 
was followed by demineralization using 0.5 M hydrochloric acid to 
eliminate the calcium carbonate.
The residue, chitin, was scrapped into a Petri dish and dried in the 
oven at 100ºC for 2 h. The chitin was then deacetylated by boiling in 
0.2 M sodium hydroxide, at 100ºC for 2 h to produce the chitosan. This 
was washed and tested with litmus paper to ensure a complete removal 
of the sodium hydroxide. Finally, the chitosan was oven dried at 90ºC 
for 24 h.
Preparation of piroxicam powder formulation: A 100 g batch 
of chitosan /piroxicam powder formulation was prepared using the 
different percentage compositions given in Table 1. Where piroxicam, 
the active drug ingredient, designated as P, was maintained at a constant 
dosage of 10 mg while the excipient, composed of the lactose (designated 
as L, which served as the filler) and the chitosan (designated as CCR 
and CCW for chitosan extracted from crab shell and cowry shell 
respectively) were varied in order to study the effects of their increasing 
weight percent on the physical, mechanical and dissolution properties 
of the formulated drug.  
Each batch of 200 mg ± 2 mg piroxicam formulated powder was 
compressed for 30 seconds into tablets with predetermined loads 
ranging from 69.36 to 208.08 MPa on a Carver hydraulic press (Model 
C, Carver Inc. Wisconsin, USA), using an eight mm die and flat faced 
punch. The dies and punches were lubricated with a 2% w/v dispersion 
of magnesium stearate and talc in acetone prior to each compression 
[4].  After ejection, the tablets were stored over silica gel for 24 h to 
allow for elastic recovery and prevent false low yield values [3].
Fourier Transform Infrared (FTIR) Spectroscopy: The FTIR 
spectra of chitosan obtained from crab and cowry shell (CCR and CCW) 
were recorded using an infrared spectrophotometer (Model IR Prestige 
21, Shimadzu). All the Infrared spectra were recorded at resolution of 4 
cm-1 over the frequency range from 4000-400 cm-1. Similarly the FTIR 
spectrum of the piroxicam loaded chitosan was studied to evaluate the 
interaction of the drug with the chitosan.
Analysis of particle shape and size: The morphology of the 
synthesized chitosan was studied using the scanning electron 
microscopy technique. Particle shape and size of samples from the 
synthesized materials and formulated drug were determined using 
optical microscopy. Optical images of the synthesized material were 
captured using an optical microscope (Leica Galen III Compound 
microscope with celestron digital microscope camera). The images were 
then analyzed using Image Pro Premier software (Media Cybernetics, 
Bethesda, MD, USA) in order to determine the particle descriptors of 
major and minor axis, length, perimeter and projected area. The shape 
factors, aspect ratio, roundness, irregularity and equivalent diameter 
were determined using equations (1-4).
bAspect Ratio
l
=                                                     (1)
pIrregularity
l
=                                                           (2)
Figure 1: Structure of piroxicam.
Figure 2: Structure of chitosan.
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pIrregularity
l
=                                                      (3) 
( ) 2 AEquivalent Circle Diameter ECD
x
= ∗                                        (4) 
(Where; b = Length of the minor axis, minimum Feret diameter, l = 
Length of the major diameter, maximum Feret diameter, A = Projected 
area of the particle and P = Perimeter)
Dissolution test for piroxicam tablet formulation: The dissolution 
rate of the piroxicam tablet was determined at 37 ± 0.5°C in 750 ml of 
0.1 M hydrochloric acid using a Veego dissolution testing station and a 
stirring speed of 100 revolutions per minute.  The tablet was placed in 
the rotating basket and 5 ml of the medium was sampled with a pipette 
after every 30 minutes. The same quantity of the medium was added 
at the same temperature immediately after each sampling to keep the 
volume of the dissolution medium constant. After 2 h of testing in 0.1 M 
of hydrochloric acid, the operation was completed by adding buffer and 
adjusting the pH within 5 minutes. With the apparatus in operation, 250 
ml of 0.20 M solution of di-potassium hydrogen orthophosphate that 
has been equilibrated to 37 ± 0.5°C was added and it was adjusted with 
31 ml of 2.0 M of sodium hydroxide to a pH of 6.8 ± 0.05. The operation 
was continued for 4 h. The concentration of dissolved piroxicam in the 
medium was determined spectrophotometrically using a Unicam 8620 
UV/visible spectrophotometer (Pye Unicam, UK) at a wavelength of 
360 nm. All determinations were made in triplicate and the results were 
given as average values.
Results and Discussion
Fourier Transform Infrared (FTIR) Spectroscopy 
The FTIR spectra for biopolymer extracts and the formulated 
piroxicam powder are presented in Figure 3. These spectra confirmed 
that the structures of the two different chitosan are indeed chitosan. (6, 
21) It is reported that the FTIR spectrum of chitosan exhibits major 
bands at 3444 cm-1, 2919 cm-1, 1659 cm-1, 1420 cm-1, 1080 cm-1 and 
1033 cm-1 corresponding to OH group (3444 cm-1), stretching of CH2 
(2919 cm-1), amide I band (1659 cm-1), vibration of OH ring (1420 cm-
1), stretching of CH (1080 cm-1) and –C-O-C linkage (1033 cm-1). These 
bands, which are the main characteristic bands of chitosan [18,24], are 
similar to those observed in the spectrum of the chitosan synthesized 
from the crab and cowry shells, CCR and CCW (Figure 3), i.e., 3448.84 
cm-1, 2931.90 cm-1, 1654.98 cm-1, 1429.3 cm-1, 1070.53 cm-1 and 1033.88 
cm-1 Similarly, NH stretching bands are found in the spectrum of CCR 
and CCW at 3109.35 cm-1 and 3232.08 cm-1 which is similar to what was 
observed by Mohammed et al. [17]. Consequently, it can be stated that 
the biopolymer extracts from crab and cowry shell are chitosan.
In addition, the absorption bands used to distinguish protein 
(1540 cm-1) and mineral (1798 and 876 cm-1) were not observed in the 
spectrum. The absence of both protein and mineral matters indicate that 
the materials may not elicit any cyto-toxic or adverse immunological 
response in the host when administered.   
Furthermore, the spectrum of P-CCR and P-CCW, Figure 3b, 
displays absorption bands at 3448.84 cm-1, 3338.89 cm-1, 3103.57 cm-1, 
2931.90  cm-1, 2521.05 cm-1, 1629.90 cm-1, 1577.82 cm-1, 1529.60 cm-
1, 1435.09 cm-1, 1352.14 cm-1, 1300.07 cm-1, 1215.19 cm-1, 1182.40 cm-
1, 1149.61 cm-1, 1120.68 cm-1, 1039.67 cm-1, 991.44 cm-1, 939.36 cm-1, 
875.71 cm-1, 831.35 cm-1, 773.48 cm-1, 732.97 cm-1, 690.54 cm-1, 619.17 
cm-1, 565.16 cm-1, 526.58 cm-1 and 457.14 cm.-1 It can be observed that 
the bands of chitosan were separated from that of piroxicam showing 
that there is no interaction between the chitosan obtained from crab 
shell (CCR) and the active pharmaceutical ingredient, piroxicam. A 
similar trend was observed in the spectrum of P-CCW, which displays 
absorption bands at 3853.90 cm-1, 3736.24 cm-1, 3446.91 cm-1, 3338.89 
cm-1, 2931.90 cm-1, 2521.05 cm-1, 1791.93 cm-1, 1629.90 cm-1, 1525.74 
cm-1, 1479.45 cm-1, 1435.09 cm-1, 1352.14 cm-1,  1300.07 cm-1, 1215.19 
cm-1, 1182.40 cm-1, 1149.61 cm-1, 1039.67 cm-1, 939.36 cm-1, 860.28 
cm-1, 831.35 cm-1, 773.48 cm-1, 732.97 cm-1, 626.89 cm-1, 565.16 cm-1, 
526.58 cm-1, 457.14 cm-1 and 418.57 cm-1 indicating that there was no 
interaction between chitosan obtained from cowry shell (CCW) and 
piroxicam.
Dissolution properties of piroxicam tablets
The dissolution results, presented in the form of percentage drug 
released with time, are shown in Figures 4-6. Generally, polymer 
dissolution and erosion take place in three steps: Solvent penetration 
into the polymer matrix, polymer chain disentanglement and 
attainment of the threshold disentanglement. When solvent penetrates 
into the polymer matrix, it enhances the mobility of the polymer chains 
which eventually disentangle at the advancing front, separating the 
 
(a)  
 
(b) 
Figure 3: FTIR spectrum for (a) chitosan and (b) the formulated piroxicam/
chitosan powder.
Figure 4: Plots of % drug released with time (min) for piroxicam tablets 
compressed at 104.04 (MPa).
Figure 5: Plots of % drug released against time (mins) for piroxicam tablets 
compressed at 138.72 (MPa).
Figure 6:  Plots of % drug released against time (min) for piroxicam tablets 
compressed at 173.40 (MPa).
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bond layer from the erosion/dissolution front. Chitosan disentangles 
as solvent passes through the pores, which provided an avenue for the 
drug release rate to increase. Thus, the synthesized chitosan was found 
to be an effective rate controlling polymer; by increasing the amount of 
chitosan (CCR/CCW) the drug release rate was observed to increase 
for the different formulations that were compressed using different 
compacting pressure as shown in Figures 4-6.
Effect of changes in compacting pressure and time on the drug 
released rate for the formulated tablets can be observed in Figures 4-6. 
Increase in the amount of drug released was observed with increasing 
time for all the formulation. However, the applied compacting pressure 
was also found to have influenced the drug release rate. The time 
taken for 50% of drug to be released for formulations manufactured 
using different compression forces indicated that drug release become 
slower with increasing applied force. This effect is particularly notice 
when comparing tablets manufactured using a very low compression 
force of 104.04 MPa with the tablets manufactured at higher 
compression forces of 138.72 MPa and 173.40 MPa. Depending on the 
compressibility behavior of the piroxicam powder, the porosity of the 
matrices was reduced with increasing compression force. This resulted 
in slower media uptake and media front movement into the matrix and 
consequently slow drug release rate.  
Furthermore, the observed drug release rate was found to be higher 
in the formulations that had no lactose, the (10-90%) P-CCW and 
P-CCR formulation, compressed using different compressive forces. It 
can be noted that the piroxicam in the tablets were released before 6 
hours. This may be due to the absence of lactose which serves as filler 
in the drug matrix. Lactose in the matrix results in lower porosity 
of the compacted tablet, hence lower drug release rate. Increasing 
concentration of lactose however resulted in improved osmotic pressure 
that may lead to accelerated water penetration into the matrix, resulting 
in a higher degree of polymer swelling and formation of more micro-
cavities [22]. Lactose, being water-soluble, produces more pores when 
in contact with water, forming more micro-cavities during the various 
mesophase formations. This causes the osmotic effect which promotes 
the erosion of chitosan [26] and subsequently the observed increase in 
the drug released from the matrices with increasing concentration of 
lactose. The lactose was therefore found to shortens the penetration 
time of the dissolution medium into the matrix and to also acts as a 
channeling agent by rapidly dissolving and easily diffusing outward, 
therefore increasing the matrix porosity with time. Consequently, the 
lactose was found to enhance the achievement of predetermined drug 
release profiles in the chitosan based controlled release matrices.
Microscopic and morphological properties of the samples 
Optical microscopic imaging and quantitative image analyses have 
advanced the morphological characterization of powders, and the 
subsequent ability to use the knowledge acquired from such exercise to 
make important decisions during powder handling and the formulation 
of pharmaceutical dosage forms. Various morphological descriptors 
have been proposed and used by different image analysis software 
[1,5,7]. The results of the shape descriptors study carried out on the 
powdered samples of the synthesized materials, which include the 
aspect ratio, elongation, roundness, irregularity and equivalent circle 
diameter are presented in Table 2. From the result, it can be observed 
that all the samples have roundness value less than one. Roundness is 
a measure of how closely the projected area of the particle resembles a 
circle; with a perfect circle having a roundness value of 1. The higher the 
roundness value, the higher the percentage porosity, the better the flow 
rate. The CCR and CCW have higher roundness values (0.82 and 0.85 
respectively) when compared to what was obtained for the different 
drug formulations. Consequently, they are less densely packed and have 
higher porosity. Correspondingly, P-CCW and P- CCR (10-90%)  has 
the highest roundness value of 0.64 and 0.68 respectively in the drug 
formulation. Thus, they have higher porosity and higher rate of release 
of the active drug ingredient (Figures 4-6). 
Aspect ratio takes into consideration the maximum and minimum 
Feret’s diameter and these are utilized in the calculation of length and 
breadth of the particle (5, 1). It may be noted that the P-CCRL (10-35-
55%)  has the lowest aspect ratio of 0.19. This may be responsible for 
its good packing properties, low percentage porosity and subsequently 
the observed low delivery of piroxicam, when compared to the 
other formulation. Similarly, irregularity measures the surface area 
compared to the size of the particle. A perfect circle, for example, has 
an irregularity of π [1,15,37,38]. In the powder formulation, it can be 
observed that P-CCW (10-90%) has the highest irregularity value of 
2.94 while P-CCRL (10-35-55%) has the lowest is 2.29. These results 
further support the result of the aspect ratio and also the results obtained 
from SEM analysis (Figure 7) and proved that the powders were far 
from being perfect circles. These parameters may be responsible for 
the formulation having only CCR and CCW; which has the highest 
roundness value, highest irregularity and aspect ratio, hence closest to 
having circular configuration of all the samples. This resulted in it being 
less densely packed, consequently its high porosity, which led to the 
observed high drug release rate (Figures 4-6). In the same vein, it may 
be noted that P-CCRL (10-35-55%) that has the lowest aspect ratio of 
2.29 is more densely packed, hence it has low porosity and consequently 
low drug release rate. 
The particle size of the samples was determined using the equivalent 
circle diameter (ECD), which measures the diameter of a circle having 
the same cross sectional area as the powder. The higher is the ECD, the 
larger the mean particle size [9]. Particle size had also been reported 
to affect the flow and packing properties of powder systems and their 
behavior during procedures involving bulk powder handling [16,19]. 
From Table 3, the extracted biopolymer, CCR and CCW, have lowest 
particle size, 9.07 and 9.00 respectively, this may be responsible for 
Ingredients (%)
Formulation
P-CCR/ P-CCW
 (10-90)
P-CCRL/P-CCWL (10-
75-15)
P-CCRL/P-CCWL (10-
65-25)
P-CCRL/P-CCWL (10-
55-35)
P-CCRL/-CCWL (10-
45-45)
P-CCRL/P-CCWL (10-
35-55)
Piroxicam (P %) 10 10 10 10 10 10
(CCR/CCW %) 90 75 65 55 45 35
Lactose (L%) - 15 25 35 45 55
Table 2: Chitosan piroxicam powder formulation.
  
b  c a 
Figure 7: SEM micrographs of chitosan at magnifications of (a) 500 (b) 3,000 
and (c) 10,000.
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their high percentage porosity, hence the observed delivery rate 
(Figures 3-6). In the piroxicam formulations, P-CCRL (10-35-55%) 
has the highest particle size. The larger the particles size, the lower the 
percentage porosity of the formulated powder and the lower the rate of 
release of the active ingredient.
Conclusion
The FTIR spectra indicated that the biopolymer extracts were 
chitosan and that there was no interaction between piroxicam and 
the biopolymer extracts. The inclusion of lactose in the piroxicam 
formulation resulted in tablets with low porosity because the lactose 
served as filler, which fills the pores of the piroxicam tablets during 
compression and thus enhanced the sustain release of piroxicam; 
however, the release rate has been found to also depend on time, 
compression pressure and the percentage of lactose and chitosan used 
in the formulation.
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